Fusion Antibodies (LON:FAB) Stock Price Up 12.8% – Still a Buy?

Shares of Fusion Antibodies plc (LON:FAB) traded up 12.8% during mid-day trading on Thursday . The company traded as high as GBX 7.95 ($0.10) and last traded at GBX 7.95 ($0.10). 981,343 shares were traded during trading, a decline of 16% from the average session volume of 1,166,639 shares. The stock had previously closed at GBX 7.05 ($0.09).

Fusion Antibodies Trading Up 11.1 %

The company has a 50 day moving average of GBX 5.28 and a two-hundred day moving average of GBX 4.11. The stock has a market capitalization of £7.47 million, a PE ratio of -195.83 and a beta of 0.49. The company has a debt-to-equity ratio of 2.40, a quick ratio of 2.36 and a current ratio of 3.87.

Insider Transactions at Fusion Antibodies

In related news, insider Adrian Kinkaid purchased 83,728 shares of the firm’s stock in a transaction on Wednesday, October 16th. The stock was acquired at an average price of GBX 4 ($0.05) per share, with a total value of £3,349.12 ($4,190.59). Insiders own 11.39% of the company’s stock.

Fusion Antibodies Company Profile

Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies primarily for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally. The company offers monoclonal antibody discovery and development, antibody sequencing, antibody engineering, antibody humanization and rational affinity maturation platform, recombinant protein expression, and stable cell line development and cGMP scale up services.